Agilent Technologies, Inc., TOMY DIGITAL BIOLOGY CO.,LTD and Twist Bioscience are Dominating the Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostics Market in 2019

Asia-Pacific Next Generation Sequencing (NGS) In Cancer Diagnostics Market is expected to grow with the CAGR of 21.9% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-next-generation-sequencing-ngs-in-cancer-diagnostic-market

Asia-Pacific next generation sequencing (NGS) in cancer diagnostics market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Asia-Pacific next generation sequencing (NGS) in cancer diagnostics market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in May 2020, ArcherDX, Inc. collaborated with Bayer in order to develop the companion diagnostic (CDx) for Vitrakvi (larotrectinib) which utilize the next generation sequencing technology (NGS). This collaboration done by the company will strengthen its cancer diagnostics segment in the market.

Agilent Technologies, Inc.is the dominating player in Asia-Pacific next generation sequencing (NGS) in cancer diagnostics market. The other key players existing in the market includes Twist Bioscience, Millennium Science Pty Ltd, Dow Biomedica Co., Spinco Biotech Pvt Ltd, Quantabio, Swift Biosciences Inc., ArcherDX, Inc., Premas Life Sciences and TOMY DIGITAL BIOLOGY CO., LTD., among others.

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic MarketAgilent Technologies, Inc.:

Agilent Technologies, Inc. incorporated in 1999, headquarters in California, U.S. The company is engaged in providing laboratories across globe with instruments, services, consumables, applications and expertise. The company is associated with life sciences, diagnostics and applied chemical markets The company is providing products under analytical instruments and supplies, life science, clinical & diagnostic testing, lab management & consulting, lab supplies, lab automation, lab software, dissolution testing, vacuum & leak detection product categories. The market focus products lie under life science product category. The company is engaged in continuous distribution of the next generation sequencing (NGS) in cancer diagnostic.

  • In March 2020, Agilent Technologies, Inc. launched three new microarrays to address the requirements of prenatal and postnatal research in cytogenetic laboratories. These new product launched by the company increases its NGS product portfolio leading to increased demand for its products in future.

The company has a wide presence across Asia-Pacific, Europe, North America and South America. The company has various subsidiaries like Agilent Technologies Rhone AG (Switzerland), AT Singapore (Global) Pte Ltd (Singapore), Agilent Technologies World Trade, Inc (U.S.), Agilent Technologies Singapore (Holding) Pte. Ltd.(Singapore) and Agilent Technologies Singapore (International) Pte. Ltd. (Singapore), among others.

TOMY DIGITAL BIOLOGY CO., LTD.

TOMY DIGITAL BIOLOGY CO.,LTD headquartered in Tokyo, Japan was founded in 1958. The company focuses on providing high quality instruments and superior services to customers across various industry segments, including biotechnology, biological engineering, medical science and food development. The company is providing products under manufactured products and allianced products. The market focus products lie under allianced product category. The company has initiated many strategic initiatives to expand its market.

  • In November 2019, TOMY DIGITAL BIOLOGY CO.,LTD. underwent a partnership with WASAI Technology Inc. in order to distribute the genome sequencing solutions of the WASAI Technology Inc. in Japan region. This partnership done by the company has increased its demand in the Asia-Pacific region leading to increased sales and revenue of its product in the market.

The company has a wide presence across Asia-Pacific. The company also has various subsidiary companies such as TOMY SEIKO CO.,LTD. (Japan), TOMY KOGYO CO., LTD. (Japan), TOMY MANAGEMENT SERVICE CO., LTD. (Japan), TOMY MEDICO CO., LTD. (Japan) and TOMY OKINAWA NOVO SCIENCE CO., LTD. (Japan).

Twist Bioscience:

Twist Bioscience was incorporated in 2013. The company focuses in synthetic biology and has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company is engaged in providing products in categories like SARS-COV-2 tools, genes, oligo pools, variant libraries, DNA data storage, NGS and biopharma among which NGS is the market focused category.

  • In February 2020, Twist Bioscience collaborated with Miroculus Inc., an upcoming leader in the field of NGS workflow automation in order to bring next-generation sequencing target enrichment and library preparation tools for clinical research. This collaboration will strengthen the NGS product portfolio of the company and leads to increased demand in future.

The company has a wide presence across North America, Europe, Middle East & Africa and Asia-Pacific. The company has various subsidiary companies such as Twist Bioscience Worldwide (Cayman Islands), Twist Bioscience Israel Ltd (Israel), Twist Bio Computing, LLC (U.S.), Twist Pharmaceutical Solutions, LLC (U.S.) and Twist Bioscience Singapore PTE. LTD. (Singapore) among others. The company has initiated many strategic initiatives to expand its market.